Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. American Health & Drug Benefits.
What Costs Can a U.S. Health Plan Expect If An Enrollee Has Chronic Thromboembolic Pulmonary Hypertension? A Guideline-based Estimate of Healthcare Resource Use and Cost. Poster presentation at CHEST World Congress
Guideline Based Estimates of Diagnostic and Treatment-related Resource Use and Costs of A Typical Pulmonary Arterial Hypertension Patient to U.S. Health Plan. Poster presentation at CHEST World Congress,